Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc. is listed today as Whitehawk Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2025 | $100 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Sep 2022 | $73 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Aug 2021 | $155 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Mar 2017 | $42 M | Private placement after listing | $10 to $50 million | equity, options | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Whitehawk Therapeutics, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $7.14 million (100%).
Annual report (SEC XBRL) · Dec 2025
Aerpio Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2025).
SEC Form D · Mar 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2025
Products and services#
No products or services of Aerpio Pharmaceuticals, Inc. are on record.
Investors#
No investor of Aerpio Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today
Institutions holding Whitehawk Therapeutics, Inc. shares, as of Sep 30, 2026.
- Yu Fan$18 M8.18%
- Acuta Capital Partners, LLC$18 M7.94%
- QVT Financial LP$17 M7.82%
- Montanova Capital, LLC$16 M7.07%
- Orbimed Advisors LLC$14 M6.53%
- Avoro Capital Advisors LLC$11 M4.83%
- BlackRock, Inc.$10 M4.39%
- Siren, L.L.C.$9 M3.96%
- KVP Capital Advisors, LP$8 M3.67%
- Vanguard Capital Management LLC$6 M2.48%
- ADAR1 Capital Management, LLC$5 M2.27%
- Geode Capital Management, LLC$4 M1.79%
- Acorn Capital Advisors, LLC$4 M1.58%
- Renaissance Technologies LLC$2 M1.13%
- State Street Corp$2 M1.00%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Bryan Ball | Executive officer | Mar 2025 |
| Dave Lennon | Executive officer | Mar 2025 |
| David Dornan | Executive officer | Mar 2025 |
| Scott Giacobello | Executive officer | Mar 2025 |
| Brendan Delaney | Executive officer | Oct 2022 |
| Loretta Itri | Executive officer | Oct 2022 |
| Neil Desai | Executive officer | Oct 2022 |
| Lance Thibault | Executive officer | Sep 2021 |
| James M. Murphy | Executive officer | Mar 2017 |
| Joseph Gardner | Executive officer | Mar 2017 |
| Kevin G. Peters | Executive officer | Mar 2017 |
| Stephen G. Pakola | Executive officer | Mar 2017 |
| Anupam Dalal | Director | Mar 2025 |
| Baiteng Zhao | Director | Mar 2025 |
| Behzad Aghazadeh | Director | Mar 2025 |
| Caley Castelein | Director | Mar 2025 |
| Dave Lennon | Director | Mar 2025 |
| Emma Reeve | Director | Mar 2025 |
| Karin Hehenberger | Director | Mar 2025 |
| Mohammad Hirmand | Director | Mar 2025 |
| Neil Desai | Director | Mar 2025 |
| Richard Maroun | Director | Mar 2025 |
| Karin Heneberger | Director | Sep 2021 |
| Anupam M. Dalal | Director | Mar 2017 |
| Caley M. Castelein | Director | Mar 2017 |
| Chau M. Khuong | Director | Mar 2017 |
| Joseph Gardner | Director | Mar 2017 |
| Muneer Satter | Director | Mar 2017 |
| Paul M. Weiss | Director | Mar 2017 |
| Pravin M. Dugel | Director | Mar 2017 |
| Steven M. Prelack | Director | Mar 2017 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.